N

Natera

Genetic testing for cancer, transplant, pregnancy

Associate Director/Senior Manager - Health Economics & Outcomes Research-Oncology

Full-TimeUpdated on 10/2/2026
$157k - $239.8k/yr+ Annual performance incentive bonus + Long-term equity awards
Senior, Expert
Bachelor's, Master's, PhD
Remote in USA
Remote
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • An advanced degree (PhD, PharmD, MD, DrPH, or Master's degree) in Health Economics, Outcomes Research, Epidemiology, Public Health, Biostatistics, Pharmacy, Health Services Research, or a related discipline is required.
  • At least 5 years of HEOR experience within biotechnology, pharmaceuticals, diagnostics, medical devices, consulting, academia, or a related healthcare environment is required.
  • Demonstrated experience developing and applying health economic models and conducting outcomes research using clinical-trial and/or real-world datasets is required.
  • Experience supporting payer evidence generation, reimbursement strategy, value dossiers, market access initiatives, and scientific publications is required.
Responsibilities
  • Lead the development, validation, and application of health economic models, including budget impact, cost-effectiveness, cost-utility, cost-consequence, return on investment, decision-tree, Markov/state-transition, partitioned-survival, and other economic models.
  • Develop scenario and sensitivity analyses that quantify the clinical and economic value of precision diagnostics across different payer and healthcare-system perspectives.
  • Partner with Clinical Development, Medical Affairs, Biostatistics, and other cross-functional teams to integrate HEOR objectives into prospective clinical studies, including healthcare resource utilization, economic endpoints, patient-reported outcomes, quality-of-life measures, cost-data collection, and real-world evidence strategies.
  • Ensure evidence-generation plans anticipate future payer, reimbursement, and health technology assessment requirements.
  • Analyze clinical-trial, observational, and real-world datasets to evaluate healthcare resource utilization, cost of care, treatment pathways, diagnostic utilization, clinical utility, comparative effectiveness, patient outcomes, survival, budget impact, and quality-adjusted life years.
  • Translate research findings into actionable evidence supporting clinical, payer, and business decisions.
  • Lead HEOR publication strategy and develop peer-reviewed manuscripts, scientific abstracts, conference posters, oral presentations, white papers, and technical reports.
  • Coordinate publication plans and timelines with investigators, key opinion leaders, academic collaborators, and external research partners.
  • Partner with Market Access, Medical Affairs, Marketing, and Commercial teams to translate HEOR evidence into payer value propositions, budget impact summaries, value dossiers, reimbursement materials, health economic briefs, health-system value calculators, account-specific economic tools, and other evidence-based value communications.
  • Develop and adapt health economic evidence and payer models for the United States and international markets, including Europe, Japan, Canada, Australia, and other priority geographies.
  • Support reimbursement submissions and evidence strategies aligned with health technology assessment and payer requirements across healthcare systems.
  • Serve as a strategic HEOR partner across Medical Affairs, Clinical Development, Biostatistics, Market Access, Commercial, Marketing, Regulatory, and Business Development.
  • Collaborate with external consultants, academic investigators, key opinion leaders, and research partners to execute evidence-generation initiatives.
Desired Qualifications
  • Experience with precision medicine, molecular diagnostics, companion diagnostics, circulating tumor DNA, molecular residual disease, donor-derived cell-free DNA, next-generation sequencing, biomarker-guided treatment strategies, or oncology diagnostics.
  • Familiarity with Microsoft Excel, TreeAge Pro, R, SAS, Stata, Python, SQL, Tableau, Power BI, and statistical analysis software.
  • Understanding of United States and international reimbursement environments and major health technology assessment frameworks, including ICER, NICE, CADTH, PBAC, IQWiG, and Japanese reimbursement processes.

About the company

Natera provides genetic testing and diagnostics using cell-free DNA (cfDNA) from a patient’s blood to guide medical decisions. Its tests include MRD and ctDNA profiling for cancer, the personalized Signatera test, organ transplant health assessment, and Panorama NIPT for prenatal screening. The company combines cfDNA-based results with remote access and genetic counseling to support clinicians and patients. Its goal is to deliver accurate, noninvasive tests that improve treatment decisions and patient outcomes at scale.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Get referred to Natera

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $752.8 million, up 37.7%, and guidance rose to $2.85-2.91 billion.
  • Signatera volumes reached 283,000 units in Q2 2026, proving commercial pull across tumor types.
  • Japan bladder-cancer launch in 2027 plus EU IVDR access extends Signatera’s addressable market sharply.

What critics are saying

  • August 2026 class-action settlement over Panorama closes one reputation wound, not the litigation burden.
  • Schneider securities suit, Copley billing claims, and Klein PGT-A litigation keep legal overhang alive.
  • ArcherDX’s September 2026 Federal Circuit appeal threatens Natera’s patent moat and future MRD pricing.

What makes Natera unique

  • Natera’s Signatera owns tumor-informed MRD with PMDA and FDA bladder-cancer approvals, August 2026.
  • June 2026 PMDA approval made Signatera Japan’s first approved MRD test in colorectal cancer.
  • Natera combines oncology, prenatal, and transplant testing on one cfDNA platform, widening physician penetration.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 1%
Yahoo Finance
Sep 24th, 2026
Natera's Signatera wins Japan PMDA approval as bladder cancer companion diagnostic

Natera's Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency as a companion diagnostic for muscle-invasive bladder cancer. The approval supports Signatera-guided decisions for adjuvant atezolizumab treatment and marks the company's second PMDA authorisation for Signatera in three months. Natera plans to commercially launch Signatera for MIBC in Japan in the first half of 2027. The regulatory approval was supported by data from the IMvigor011 Phase III clinical trial, which included more than 20 participating sites in Japan. Bladder cancer affects more than 34,000 people annually in Japan, with approximately 20-25% of newly diagnosed cases classified as MIBC. Following the announcement, Natera stock gained 5.5%.

MarketScreener
Sep 18th, 2026
Natera presents largest MRD dataset in lung cancer at IASLC 2026 world conference.

Natera presents largest MRD dataset in lung cancer at IASLC 2026 world conference. Published on 09/18/2026 at 07:05 am EDT S&P Capital IQ Natera and its collaborators presented four abstracts, including two oral presentations. A mini-oral presentation featured the largest molecular residual disease (MRD) dataset ever presented in lung cancer. This analysis of 1,129 patients with resected stage 1-3 non-small cell lung cancer (NSCLC) spanned an observation period from 2016 to 2025. Signatera MRD detection was evaluated in the early post-surgical window and throughout surveillance, with the following key findings: Early post-surgical Signatera-status was strongly prognostic of recurrence-free survival. Signatera-positivity in the early post-surgical window (7?90 days after surgery) was associated with significantly worse recurrence-free survival (RFS), with a 25% higher absolute 3-year RFS for Signatera-negative patients. Signatera-positive patients had approximately 5X the risk of recurrence or death during surveillance. Findings were consistent across both the primary surgical and perioperative cohorts, supporting broad applicability of Signatera monitoring across resected stage 1-3 NSCLC. Full list of presentations at WCLC 2026 included: Abstract P2.192 Poster: ctDNA After Definitive Therapy +/- Immunotherapy and Association with Survival Outcomes in Locally Advanced Unresectable NSCLC. Abstract P2.200 Poster: ctDNA-based Molecular Residual Disease as a Predictive Biomarker for Treatment Stratification in Unresectable Stage 3 NSCLC. Abstract MO05.07 Mini Oral: KRAS G12C Predicts Superior Outcomes with 1L Cemiplimab for Non-Squamous aNSCLC With PD-L1 = 50%: Data From EMPOWER-Lung 1. Abstract MO11.09 Mini Oral: Post-Surgical Molecular Residual Disease Detection, Adjuvant Treatment Patterns, and Overall Survival in Resected Stage 1-3 NSCLC. (C) S&P Capital IQ - 2026

Resonate Group Incorporated
Aug 31st, 2026
Natera teams with Angiex on cancer drug trial monitoring.

Natera teams with Angiex on cancer drug trial monitoring. * August 31, 2026 Natera inked a collaboration deal with biotech Angiex to assess the use of its Signatera blood test, which looks for small traces of cancer DNA in patients who have been diagnosed and treated for the disease.

Yahoo Finance
Aug 26th, 2026
Natera supplies MRD assay for Kupando's Phase 1 skin cancer immunotherapy trial

Natera has partnered with Kupando Therapeutics to supply its Latitude tissue-free minimal residual disease (MRD) assay for a Phase 1 immunotherapy trial in multiple skin cancers. The assay will monitor disease and treatment response in patients receiving Kupando's investigational therapy. The collaboration extends Natera's MRD technology into early-stage drug development settings. Natera is a US-based molecular diagnostics company that develops and commercialises testing services. The partnership expands Natera's presence in oncology clinical trials and supports use of its MRD technology across different tumour types. However, the revenue impact from these early-stage trial deployments is likely modest at this stage. Investors will watch whether additional oncology trials adopt Natera's platforms and if the company begins disclosing trial counts or patient volumes linked to MRD collaborations.

Yahoo Finance
Aug 15th, 2026
Natera beats Q2 estimates with $753M revenue as Signatera oncology test drives 37.7% growth

Natera reported second-quarter results that beat analyst expectations, driven by strong test volume growth and momentum across its product portfolio. Revenue reached $752.8 million, exceeding estimates by 13.6%, whilst adjusted EPS of -$0.47 beat forecasts. CEO Steven Chapman attributed the performance to record test volumes, particularly for Signatera in oncology, and the launch of an enhanced Panorama prenatal test. The company secured FDA and Japanese regulatory approvals for Signatera during the quarter. Operating margin improved to -10.1% from -20.2% year on year. Sales volumes rose 22.4% compared to the prior year. During the earnings call, analysts questioned the sustainability of Signatera's growth trajectory and future pricing potential. Chapman acknowledged emerging competition in MRD testing but noted that low market penetration leaves substantial room for expansion.